Hemogenyx Pharmaceuticals (LSE:HEMO) Common Stock : £13.42 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals Common Stock?

Hemogenyx Pharmaceuticals's quarterly common stock increased from Jun. 2023 (£9.81 Mil) to Dec. 2023 (£11.76 Mil) and increased from Dec. 2023 (£11.76 Mil) to Jun. 2024 (£13.42 Mil).

Hemogenyx Pharmaceuticals's annual common stock stayed the same from Dec. 2021 (£9.80 Mil) to Dec. 2022 (£9.80 Mil) but then increased from Dec. 2022 (£9.80 Mil) to Dec. 2023 (£11.76 Mil).

Hemogenyx Pharmaceuticals Common Stock Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Common Stock Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

3.61

4.34

9.80

11.76

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial													9.80	9.80	9.81	11.76	13.42

Hemogenyx Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Hemogenyx Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Heddon Street, London, GBR, W1B 4BT

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

Hemogenyx Pharmaceuticals Headlines

No Headlines